Interfering with interferons in inflammatory bowel disease

    loading  Checking for direct PDF access through Ovid

Abstract

Early experience of fontolizumab, a humanised anti-interferon γ antibody, in active Crohn’s disease has shown that the drug caused a significant decrease in endoscopic severity scores and CRP and was reasonably well tolerated. Fontolizumab may be worthy of further clinical trials

Related Topics

    loading  Loading Related Articles